Eton Pharmaceuticals, Inc. Impairment of Long-Lived Assets to be Disposed of
Eton Pharmaceuticals, Inc. (ETON) reported Impairment of Long-Lived Assets to be Disposed of of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2022-08-11
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2022-06-30 was $0.00.
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2022-03-31 was $0.00.
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2021-12-31 was $0.00.
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2021-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for fiscal 2021 was $0.00.
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for fiscal 2020 was $0.00.
- Eton Pharmaceuticals, Inc. impairment of long-lived assets to be disposed of for fiscal 2019 was $0.00.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-08-11 | $0.00 derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-05-12 | $0.00 derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $0.00 derived: sum of 2 quarters · filed 2022-03-16 | $0.00 10-K · filed 2022-03-16 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | $0.00 10-Q · filed 2021-11-16 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-16 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |